Clozapine, but not haloperidol, enhances glial d -serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes

British Journal of Pharmacology

Volumn 165, Issue 5, 2012, Pages 1543-1555

  Tanahashi, Shunske ^a   Yamamura, Satoshi ^a   Nakagawa, Masanori ^a   Motomura, Eishi ^a   Okada, Motohiro ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

antipsychotics; clozapine; d serine; haloperidol; L glutamate; microdialysis

Indexed keywords

CLOZAPINE; DIZOCILPINE; FLUOROCITRIC ACID; GLUTAMIC ACID; HALOPERIDOL; SERINE; TETANUS TOXIN; TETRODOTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN REGION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEPOLARIZATION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EXOCYTOSIS; GLIA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NERVE CELL CULTURE; NERVE CELL STIMULATION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NEWBORN; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; ASTROCYTES; CELLS, CULTURED; CITRATES; CLOZAPINE; GLUTAMIC ACID; HALOPERIDOL; MALE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SERINE; TETANUS TOXIN; TETRODOTOXIN;

EID: 84857082115     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01638.x     Document Type: Article

References (39)

1. Abekawa T, Ito K, Koyama T, (2007). Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic. Naunyn Schmiedebergs Arch Pharmacol 375: 261-271.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY, (1997). Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283: 226-234.
4. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al,. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164: 1593-1602.
5. Evins AE, Amico E, Posever TA, Toker R, Goff DC, (2002). D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56: 19-23.
6. Goff DC, Henderson DC, Evins AE, Amico E, (1999). A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45: 512-514.
7. Hashimoto A, Oka T, Nishikawa T, (1995). Extracellular concentration of endogenous free d-serine in the rat brain as revealed by in vivo microdialysis. Neuroscience 66: 635-643.
8. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al,. (2005). D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57: 577-585.
9. Javitt DC, (2007). Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78: 69-108.
10. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN, (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305: 625-631.
11. Kargieman L, Santana N, Mengod G, Celada P, Artigas F, (2007). Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci USA 104: 14843-14848.
12. Kartvelishvily E, Shleper M, Balan L, Dumin E, Wolosker H, (2006). Neuron-derived d-serine release provides a novel means to activate N-methyl-D-aspartate receptors. J Biol Chem 281: 14151-14162.
13. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al,. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
14. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R, (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169: 215-233.
15. Labrie V, Roder JC, (2010). The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev 34: 351-372.
16. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, et al,. (2008). Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60: 358-403.
17. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al,. (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301-307.
18. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, et al,. (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150.
19. Martin ED, Fernandez M, Perea G, Pascual O, Haydon PG, Araque A, et al,. (2007). Adenosine released by astrocytes contributes to hypoxia-induced modulation of synaptic transmission. Glia 55: 36-45.
20. Miya K, Inoue R, Takata Y, Abe M, Natsume R, Sakimura K, et al,. (2008). Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol 510: 641-654.
21. Mothet JP, Pollegioni L, Ouanounou G, Martineau M, Fossier P, Baux G, (2005). Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter d-serine. Proc Natl Acad Sci USA 102: 5606-5611.
22. Murakami T, Okada M, Kawata Y, Zhu G, Kamata A, Kaneko S, (2001). Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis. Br J Pharmacol 134: 507-520.
23. Ninan I, Jardemark KE, Wang RY, (2003). Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48: 66-79.
24. Ohoyama K, Yamamura S, Hamaguchi T, Nakagawa M, Motomura E, Shiroyama T, et al,. (2011). Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur J Pharmacol 653: 47-57.
25. Okada M, Nutt DJ, Murakami T, Zhu G, Kamata A, Kawata Y, et al,. (2001). Adenosine receptor subtypes modulate two major functional pathways for hippocampal serotonin release. J Neurosci 21: 628-640.
26. Okada M, Zhu G, Yoshida S, Hirose S, Kaneko S, (2004). Protein kinase associated with gating and closing transmission mechanisms in temporoammonic pathway. Neuropharmacology 47: 485-504.
27. Okada M, Yoshida S, Zhu G, Hirose S, Kaneko S, (2005). Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems. Neuroscience 134: 233-246.
28. Parpura V, Zorec R, (2009). Gliotransmission: exocytotic release from astrocytes. Brain Res Rev 63: 83-92.
29. Schell MJ, Molliver ME, Snyder SH, (1995). d-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci USA 92: 3948-3952.
30. Schell MJ, Brady RO, Jr, Molliver ME, Snyder SH, (1997). d-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J Neurosci 17: 1604-1615.
31. Shim SS, Hammonds MD, Kee BS, (2008). Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 258: 16-27.
32. Sontheimer H, Waxman SG, (1993). Expression of voltage-activated ion channels by astrocytes and oligodendrocytes in the hippocampal slice. J Neurophysiol 70: 1863-1873.
33. Tsai GE, Lin PY, (2010). Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 16: 522-537.
34. Tuominen HJ, Tiihonen J, Wahlbeck K, (2006). Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev (2): CD003730.
35. Williams SM, Diaz CM, Macnab LT, Sullivan RK, Pow DV, (2006). Immunocytochemical analysis of d-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons. Glia 53: 401-411.
36. Yamamura S, Ohoyama K, Hamaguchi T, Kashimoto K, Nakagawa M, Kanehara S, et al,. (2009a). Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology (Berl) 206: 243-258.
37. Yamamura S, Ohoyama K, Hamaguchi T, Nakagawa M, Suzuki D, Matsumoto T, et al,. (2009b). Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex. Br J Pharmacol 157: 656-665.
38. Yamamura S, Abe M, Nakagawa M, Ochi S, Ueno S, Okada M, (2011). Different actions for acute and chronic administration of mirtazapine on serotonergic transmission associated with raphe nuclei and their innervation cortical regions. Neuropharmacology 60: 550-560.
39. Zhu G, Okada M, Yoshida S, Mori F, Hirose S, Wakabayashi K, et al,. (2006). Involvement of Ca(2+)-induced Ca2+ releasing system in interleukin-1beta-associated adenosine release. Eur J Pharmacol 532: 246-252.